The Universitas Gadjah Mada alumny Family FK-KMK Central Sulawesi Compartment

in collaboration with Faculty of Medicine Universitas Tadulako


Background

The National Health Insurance Program has an impact on the services of healthcare facility toward patients. Funding deficit is one of the factors that can cause non-optimum hospital service quality by reducing funding for drugs and adjunctive health equipment such as drugs and consumables, which will inhibit the doctors’ performance in treating patients.

The Indonesian Constitution of 1945, article 34 paragraph 2 stated that “The country develops a social insurance system for all population and empower weak and poor community according to human dignity.” The Indonesian Constitution of 1945, article 28H paragraph 3 stated that “Every person has the right to social insurance which allows their development as a whole and useful human being.”

The national social insurance is a form of social protection to ensure that all people can meet their basic needs of life. Thus, a legal entity was formed to implement social insurance program in Indonesia. Social Insurance Fund is a trust fund owned by all participants, which is a set of contributions and the result of development managed by Social Insurance Administration Organization (Badan Penyelenggara Jaminan Sosial; BPJS) for payment of benefits to the participants and operational funding for social insurance program. The participants are all people, including foreigners who works for at least 6 (six) months in Indonesia. In this regard, the contribution in the form of money is paid regularly by the participants, employers, and/or government. National Social Insurance System is a form of social protection managed by Indonesian Government to ensure that all people can fulfill their basic needs.

The Health Social Insurance Administration Organization (BPJS) is formed so that the people can receive free medical treatment in all community health centers, BKIA, and Qualified Government Hospitals, through increasing services and addition of facilities. Currently, health services in all community health centers or hospitals are considered not optimum because of insufficient facilities and lack of human resources and poor patients’ assessment regarding the services that they received. Therefore, community health centers and hospitals should improve their service quality. The people not only questioned whether their need of service was met or not, but also the service quality that they received from the government. In the end, the people’s trust keeps decreasing, especially in the health industry in Indonesia.

In the past years, the media had written about problems often complained regarding BPJS services, such as card activation process. BPJS implemented a rule that the card is activated a week after registration. Even though, disease and illness can occur unexpectedly and cannot be delayed. BPJS patients can only choose one healthcare facility for referral and they cannot go to other healthcare facilities, despite their cooperation with BPJS. Other problems involve the difficult tiered flow of service. Before going to the hospital, the participants should first go to the first tiered healthcare facility (Fasilitas kesehatan tingkat pertama; FKTP), which is community health centers. Other than that, there are problems of delayed claim to the hospital and other problems that occurred in the last 5 years since the launch of BPJS in 2014 in Indonesia as mandatory health insurance.

Seminar Theme

Beyond National Health Care System in Indonesia Toward Universal Coverage 2020.

Seminar Objectives
  1. Improve professionality of healthcare services, especially in the field of medicine.
  2. As a media for coaching and developing healthcare staff competence in their role in facing Universal Coverage 2020.
  3. Comparing health systems in developed countries and Indonesia in facing Universal Coverage.
  4. Creating a work synergy and interprofessional between healthcare staffs.
  5. Develop research network and other cooperation in the field of medicine, both in and outside the country.
Seminar Benefits
  1. Improvement of health service system in Indonesia, especially in Central Sulawesi.
  2. Improvement of professional healthcare staff quality.
  3. Improvement of synergic coordination between healthcare staffs in Central Sulawesi.
  4. Improvement of lecturer, student, and researcher’s interest in research publication.
Seminar Participants

Participants consist of academics (lecturers, researchers, students) and practitioners from specialists/doctors/dentists, nurses, midwives, public health, and related healthcare staffs, both in and outside the country.

Program
  1. Seminar
  2. Oral presentation
  3. Poster presentation
  4. Medical and pharmacy Expo

Speaker


 

Dr. dr. Terawan Agus Putranto, Sp.Rad (K)
Minister of Health of The Republic of Indonesia
Rencana Kebijakan dan Strategi Sistem Kesehatan di Indonesia

Prof. Dato Dr. Syed Mohamed Aljunid, MD., M.Sc., Ph.D, FAMM., DSNS
University Kebangsaan Malaysia, Malaysia
Health care cost management in Malaysia

Prof. Dr. Supasit Pannaruthai., MD., Ph.D
Faculty of Medicine Naresuan University, Thailand
Health System Development in The Changing Disease Pattern in South East Asia

Dr. dr. H. Bayu Wahyudi, Sp.OG., MPHM., M.H.Kes., MM
BPJS Kesehatan
Sistem BPJS di Indonesia dan Evaluasinya 5 tahun

Prof. dr. Ali Ghufron Mukti, M.Sc., Ph.D
Faculty of Medicine, Public Health, and Nursing. Universitas Gadjah Mada, Indonesia
Academic Health System

Prof. Hasbullah Thabrany, MD., Ph.D, Dr.PH
Faculty of Public Health University of Indonesia, Indonesia
Global Aspect of Universial Health Care System

Prof. Dr. dr. Adi Heru Husodo., M.Sc., DCN., DLHTM.
Faculty of Medicine, Public Health, and Nursing. Universitas Gadjah Mada, Indonesia
Health System and Enviromental Health: Reducing Harm and Cost

Prof. dr. Laksono Trisnantoro., M.Sc., Ph.D
Faculty of Medicine, Public Health, and Nursing. Universitas Gadjah Mada, Indonesia
Kebijakan Asuransi Kesehatan


Registration


Important dates:
  1. Online Registration (official website)
  2. Abstract submission deadline 15 April 2020
  3. Abstract acceptance announcement 30 April 2020
  4. Full Paper Deadline 30 June 2020 (format MS Word)
  5. Presentation Deadline 10 July 2020 (format ppt)
Form Registration
Full name (With title) :  
Affiliation/institution :  
Participant : Student; Academics/Practitioner; Specialist; International Participant
Email address :  
Seminar Fee
Participant 1 Feb-31 Mar 1 Apr-17 Jul On site
Student IDR. 200.000 IDR. 250.000 IDR. 300.000
Academics/Practitioner IDR. 400.000 IDR. 450.000 IDR. 500.000
Specialist IDR. 600.000 IDR. 650.000 IDR. 750.000
International USD. 150 USD. 150 USD. 150
Payment Bank

Acc. BNI 0860402836
Panitia Seminar Internasional

And confirm to email: seminar.kagamauntad@gmail.com with subject “Payment/Name”


Call for Paper and Abstract


Areas of Research
Medical, Nursing and Health

Fee for oral presentation:
Number of article Indonesian presenter International presenter
1 article IDR 500.000 US$ 75
2nd article, etc IDR 250.000/article US$ 35/article

Selected papers are expected to be published in a SCOPUS Q4 Indexed Journal. Articles that pass the publication in the journal will incur an additional fee of US$ 120.

Guidelines for Abstract Submission

Authors must include abstracts English for 250 words maximum, and include maximum five keywords that are closely related to the substance of the article. The abstracts and keywords are typed with Times New Roman font, 11-point size, and space 1.0.

Original research, systematic reviews, and meta-analyses require structured abstracts. The abstract should provide the context or background for the study and should state the study’s purpose, basic procedures/methods (selection of study participants, settings, measurements, analytical methods), results/main findings (giving specific effect sizes and their statistical and clinical significance, if possible), and conclusions. It should emphasize new and important aspects of the study or observations, note important limitations, and not over interpret findings. Clinical trial abstracts should include items that the CONSORT group has identified as essential. Funding sources should be listed separately after the Abstract to facilitate proper display and indexing for search retrieval by MEDLINE. Because abstracts are the only substantive portion of the article indexed in many electronic databases, and the only portion many readers read, authors need to ensure that they accurately reflect the content of the article.

Full Abstract format can be downloaded here

Guidelines for Full Paper Submission

Full paper manuscripts are written typed with Times new roman font, 11-point size and space 1.0 in double column format.

Manuscript Sections

a. Title Page
General information about an article and its authors is presented on a manuscript title page and usually includes the article title, author information, any disclaimers, sources of support, word count, and sometimes the number of tables and figures. Article title. The title provides a distilled description of the complete article and should include information that, along with the Abstract, will make electronic retrieval of the article sensitive and specific.

Some journals require a short title, usually no more than 40 characters (including letters and spaces) on the title page or as a separate entry in an electronic submission system. Electronic submission systems may restrict the number of characters in the title. Author information: Each author’s highest academic degrees should be listed, although some journals do not publish these. The name of the department(s) and institution(s) or organizations where the work should be attributed should be specified.

b. Abstract
Original research, systematic reviews, and meta-analyses require structured abstracts. The abstract should provide the context or background for the study and should state the study’s purpose, basic procedures/methods (selection of study participants, settings, measurements, analytical methods), results/main findings (giving specific effect sizes and their statistical and clinical significance, if possible), and conclusions. It should emphasize new and important aspects of the study or observations, note important limitations, and not over interpret findings. Clinical trial abstracts should include items that the CONSORT group has identified as essential. Funding sources should be listed separately after the Abstract to facilitate proper display and indexing for search retrieval by MEDLINE. Because abstracts are the only substantive portion of the article indexed in many electronic databases, and the only portion many readers read, authors need to ensure that they accurately reflect the content of the article.

c. Introduction
Provide a context or background for the study (that is, the nature of the problem and its significance). State the specific purpose or research objective of, or hypothesis tested by, the study or observation. Cite only directly pertinent references, and do not include data or conclusions from the work being reported.

d. Methods
The guiding principle of the Methods section should be clarity about how and why a study was done in a particular way. Methods section should aim to be sufficiently detailed such that others with access to the data would be able to reproduce the results. In general, the section should include only information that was available at the time the plan or protocol for the study was being written; all information obtained during the study belongs in the Results section. If an organization was paid or otherwise contracted to help conduct the research (examples include data collection and management), then this should be detailed in the methods. The Methods section should include a statement indicating that the research was approved by an independent local, regional or national review body (e.g., ethics committee, institutional review board). If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the local, regional or national review body explicitly approved the doubtful aspects of the study.

e. Results
Present your results in logical sequence in the text, tables, and figures, giving the main or most important findings first. Do not repeat all the data in the tables or figures in the text; emphasize or summarize only the most important observations. Provide data on all primary and secondary outcomes identified in the Methods Section. Extra or supplementary materials and technical details can be placed in an appendix where they will be accessible but will not interrupt the flow of the text, or they can be published solely in the electronic version of the journal. Give numeric results not only as derivatives (for example, percentages) but also as the absolute numbers from which the derivatives were calculated, and specify the statistical significance attached to them, if any. Restrict tables and figures to those needed to explain the argument of the paper and to assess supporting data. Use graphs as an alternative to tables with many entries; do not duplicate data in graphs and tables. Avoid nontechnical uses of technical terms in statistics, such as “random” (which implies a randomizing device), “normal,” “significant,” “correlations,” and “sample.” Separate reporting of data by demographic variables, such as age and sex, facilitate pooling of data for subgroups across studies and should be routine, unless there are compelling reasons not to stratify reporting, which should be explained.

f. Discussion
It is useful to begin the discussion by briefly summarizing the main findings, and explore possible mechanisms or explanations for these findings. Emphasize the new and important aspects of your study and put your finings in the context of the totality of the relevant evidence. State the limitations of your study, and explore the implications of your findings for future research and for clinical practice or policy. Discuss the influence or association of variables, such as sex and/or gender, on your findings, where appropriate, and the limitations of the data. Do not repeat in detail data or other information given in other parts of the manuscript, such as in the Introduction or the Results section. Link the conclusions with the goals of the study but avoid unqualified statements and conclusions not adequately supported by the data. In particular, distinguish between clinical and statistical significance, and avoid making statements on economic benefits and costs unless the manuscript includes the appropriate economic data and analyses. Avoid claiming priority or alluding to work that has not been completed. State new hypotheses when warranted, but label them clearly.

g. References
References should follow the standards summarized in the NLM’s International Committee of Medical Journal Editors (ICMJE) Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals: Sample References webpage and detailed in the NLM’s Citing Medicine, 2nd edition (for any information please visit to https://www.ncbi.nlm.nih.gov/books/NBK7256/).

h. Tables and Figures
Tables and figures should be formatted in jpg/jpeg

Full Paper format can be downloaded here

Abstract and full paper will be sent to email: seminar.kagamauntad@gmail.com with subject “Call for abstract and paper/Name”


Venue


 

Best Wstern Plus Coco Palu
Jl. Basuki Rahmat, Birobuli Utara, Kec. Palu Sel., Kota Palu, Sulawesi Tengah 94111


Traveling


 

Leave a Comment